AstraZeneca vaccine: The controversy continues
Business Standard|May 01, 2024
The controversial AstraZeneca Covid-19 vaccine, which was banned by several countries across the globe after multiple cases of blood clots were reported in patients who were administered the jab, is back in the spotlight.
ABHIJEET KUMAR
AstraZeneca vaccine: The controversy continues

On Tuesday, British-Swedish multinational pharmaceutical and biotechnology company AstraZeneca, a prominent manufacturer of Covid-19 vaccine, that was administered to millions of people around the world, specifically most in India, admitted for the first time in court documents that its Covid-19 vaccine, sold globally under the brand names Covishield and Vaxzevria, among others, may lead to a rare, deadly side effect: Thrombosis with Thrombocytopenia syndrome (TTS).

What is the new controversy

In court documents submitted to a UK court in February, the AstraZeneca company stated that TTS can occur in very rare cases.

"It is admitted that the AZ vaccine can, in very rare cases, cause TTS. The causal mechanism is not known," it said in the However, papers, it also said that even if there is no vaccination, TTS can happen, adding that expert testimony will be required to determine causation in every individual case.

The Cambridge-headquartered company now faces a class-action lawsuit, which claims that its vaccine caused serious injuries and fatalities.

What is TTS

Denne historien er fra May 01, 2024-utgaven av Business Standard.

Start din 7-dagers gratis prøveperiode på Magzter GOLD for å få tilgang til tusenvis av utvalgte premiumhistorier og 9000+ magasiner og aviser.

Denne historien er fra May 01, 2024-utgaven av Business Standard.

Start din 7-dagers gratis prøveperiode på Magzter GOLD for å få tilgang til tusenvis av utvalgte premiumhistorier og 9000+ magasiner og aviser.

FLERE HISTORIER FRA BUSINESS STANDARDSe alt
A life that lives beyond
Business Standard

A life that lives beyond

The passing of Ratan Tata marks the loss of not only an iconic leader but also a global visionary whose influence extended far beyond business.

time-read
2 mins  |
October 11, 2024
Business Standard

Ratan Tata: The unlikely social media star

On Monday, Ratan Tata posted on social media: \"Thank you for thinking of me,\" debunking rumours about his health. Just two days later, on Wednesday, the former Tata Group chairman passed away in a Mumbai hospital at the age of 86.

time-read
1 min  |
October 11, 2024
Business Standard

Paytm appears poised for rebound

While Paytm (One97 Communications) is not completely past regulatory hurdles, its share price has gained in the last month or two. The Paytm handle migration is complete along with FDI clearance necessary for the Payment Aggregator (PA) license.

time-read
2 mins  |
October 11, 2024
Love-all, RAFA
Business Standard

Love-all, RAFA

'KING OF CLAY' TO SIGN OFF FROM PROFESSIONAL TENNIS BY THE END OF THIS SEASON

time-read
3 mins  |
October 11, 2024
Business Standard

Aman for startups

Ratan Tata was known as much for his business acumen as for his philanthropy. However, a lesser-known fact was his stellar track record when it came to startup investment.

time-read
1 min  |
October 11, 2024
RBI's inflation caution may halt FMCG rally
Business Standard

RBI's inflation caution may halt FMCG rally

Analysts suggest buying quality stocks on dips for long term

time-read
3 mins  |
October 11, 2024
Indices close marginally higher
Business Standard

Indices close marginally higher

Equity benchmark indices Sensex and Nifty settled higher on Thursday due to gains in banking, power, and industrial stocks amid a firm trend in global markets.

time-read
1 min  |
October 11, 2024
Business Standard

Oil gains after 2-day decline

Oil rose after a two-day decline as traders watched for an Israeli response to Iran's missile attack early last week, while US crude stockpiles expanded the most since April.

time-read
1 min  |
October 11, 2024
Pro-rata distribution mandate for AIFs likely to see tweaks
Business Standard

Pro-rata distribution mandate for AIFs likely to see tweaks

Final norms to ensure excuse, exclude provisions co-exist

time-read
2 mins  |
October 11, 2024
Bernstein downgrades Indian stocks on valuation concerns
Business Standard

Bernstein downgrades Indian stocks on valuation concerns

Bernstein Societe Generale Group's Asia quant strategists have downgraded Indian stocks due to valuations, while predicting further upside for Chinese equities on a policy boost.

time-read
1 min  |
October 11, 2024